KeyBanc analyst Brett Fishbin raised the firm’s price target on Integer to $139 from $123 on higher multiple, while keeping an Overweight rating on the shares. The firm believes Integer is well positioned to benefit from a multiyear tailwind in Electrophysiology, driven by the anticipated adoption of pulse field ablation technologies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>